|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 741.29 USD | -0.74% |
|
+3.19% | +4.07% |
| 12-12 | Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating | MT |
| 12-12 | European health regulator recommends approval for GSK's twice-yearly asthma drug | RE |
| Capitalization | 76.06B 64.79B 60.52B 56.94B 105B 6,889B 115B 706B 274B 3,247B 285B 279B 11,847B | P/E ratio 2025 * |
18.1x | P/E ratio 2026 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise value | 69.52B 59.23B 55.32B 52.05B 95.83B 6,297B 105B 646B 250B 2,968B 261B 255B 10,830B | EV / Sales 2025 * |
4.9x | EV / Sales 2026 * | 4.48x |
| Free-Float |
77.36% | Yield 2025 * |
0.5% | Yield 2026 * | 0.53% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -0.74% | ||
| 1 week | +3.19% | ||
| Current month | -4.99% | ||
| 1 month | +6.89% | ||
| 3 months | +32.37% | ||
| 6 months | +40.07% | ||
| Current year | +4.07% |
| 1 week | 691.86 |  | 753.61 |
| 1 month | 691.86 | | 790.98 |
| Current year | 476.49 | | 790.98 |
| 1 year | 476.49 | | 790.98 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 441 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 65 | 01/01/2001 | |
| Chief Executive Officer | 72 | 08/01/1988 | |
| Director of Finance/CFO | 54 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 84 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 01/06/1991 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.74% | +3.19% | +1.37% | -1.16% | 76.06B | |
| -1.76% | -2.34% | -34.55% | -39.04% | 58.92B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | |
| -2.24% | -4.93% | +30.25% | +215.42% | 52.48B | |
| +0.93% | -3.97% | +16.04% | -39.77% | 25.54B | |
| +1.85% | -7.39% | +127.81% | +153.95% | 18.76B | |
| -0.72% | -6.94% | +39.18% | +15.41% | 18.73B | |
| -4.52% | -5.15% | +36.59% | +998.98% | 15.67B | |
| +1.46% | +2.05% | +173.37% | +686.91% | 14.48B | |
| -0.04% | -.--% | +58.82% | +149.90% | 14.02B | |
| Average | -0.41% | -1.97% | +51.81% | +220.98% | 34.77B | |
| Weighted average by Cap. | -0.56% | -0.70% | +30.99% | +122.11% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 14.2B 12.1B 11.3B 10.63B 19.57B 1,286B 21.38B 132B 51.16B 606B 53.28B 52.15B 2,212B | 15.12B 12.88B 12.03B 11.32B 20.84B 1,370B 22.77B 140B 54.48B 646B 56.74B 55.54B 2,355B |
| Net income | 4.14B 3.53B 3.29B 3.1B 5.71B 375B 6.23B 38.44B 14.91B 177B 15.53B 15.2B 645B | 4.03B 3.43B 3.21B 3.02B 5.56B 365B 6.07B 37.44B 14.52B 172B 15.13B 14.81B 628B |
| Net Debt | -6.53B -5.56B -5.2B -4.89B -9B -592B -9.84B -60.67B -23.53B -279B -24.51B -23.99B -1,017B | -8.36B -7.12B -6.65B -6.26B -11.52B -757B -12.59B -77.65B -30.12B -357B -31.37B -30.71B -1,302B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 741.29 $ | -0.74% | 804,841 |
| 11/12/25 | 746.80 $ | +2.84% | 1,153,882 |
| 10/12/25 | 726.21 $ | +4.86% | 1,316,662 |
| 09/12/25 | 692.58 $ | -1.52% | 604,535 |
| 08/12/25 | 703.26 $ | -2.10% | 1,005,953 |
Delayed Quote Nasdaq, December 13, 2025 at 01:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition